{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 414053518
| IUPAC_name = (6''R'',7''R'')-7-{[(2''Z'')-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyimino-acetyl]amino}-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
| image = Cefpodoxime.svg
| width = 200
<!--Clinical data-->
| tradename = Generic (formerly ''Vantin'')
| Drugs.com = {{drugs.com|monograph|vantin}}
| MedlinePlus = a698024
| pregnancy_AU = B1
| pregnancy_US = B
| legal_AU = <!-- Unscheduled / S2 / S3 / S4  / S8 -->
| legal_CA = <!--                             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = Rx-only
| routes_of_administration = Oral
<!--Pharmacokinetic data-->
| bioavailability = 50%
| protein_bound = 21% to 29%
| metabolism = Negligible. Cefpodoxime proxetil is metabolized to cefpodoxime by the [[liver]]
| elimination_half-life = 2 hours
| excretion = [[Kidney|Renal]], unchanged
<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|CAS}}
| CAS_number = 80210-62-4
| ATC_prefix = J01
| ATC_suffix = DD13
| PubChem = 6335986
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB01416
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4891496
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = 7R4F94TVGY
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07650
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 3504
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1672
<!--Chemical data-->
| C=15 | H=17 | N=5 | O=6 | S=2
| molecular_weight = 427.458 g/mol
| smiles = O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)C(=N\OC)/c3nc(sc3)N)COC)C(=O)O
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C15H17N5O6S2/c1-25-3-6-4-27-13-9(12(22)20(13)10(6)14(23)24)18-11(21)8(19-26-2)7-5-28-15(16)17-7/h5,9,13H,3-4H2,1-2H3,(H2,16,17)(H,18,21)(H,23,24)/b19-8-/t9-,13-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = WYUSVOMTXWRGEK-HBWVYFAYSA-N
}}

'''Cefpodoxime''' is an oral, third-generation [[cephalosporin]] [[antibiotic]]. It is active against most [[Gram-positive]] and [[Gram-negative]] organisms. Notable exceptions include ''[[Pseudomonas aeruginosa]]'', ''[[Enterococcus]]'', and ''[[Bacteroides fragilis]]''. Currently, it is only marketed as generic preparations in the USA, according to the FDA Orange Book. It is commonly used to treat acute [[otitis media]], [[pharyngitis]], [[sinusitis]], and gonorrhea. It also finds use as oral continuation therapy when [[intravenous]] cephalosporins (such as [[ceftriaxone]]) are no longer necessary for continued treatment.

[[Zoetis]] markets cefpodoxime proxetil under the trade name <!-- (C-doxim 50Dt,drysyp,100Dt/drysyp,200 and Cv200by Neomed(India) -->'''Simplicef''' for veterinary use. The dose range in dogs is 5&ndash;10&nbsp;mg/kg body weight, administered orally, once a day.

Finecure, India markets the products under trade name Cefpo.<!-- (Cefpo 100Dt, 200, Cv and Dry Syrup) --><ref>{{cite web |title= Anti Biotics and Anti Bacterial |url=http://www.finecurepharma.com/cephalosporins.htm#cefu5 |publisher=Finecurepharmaceuticalsltd | accessdate=2012-03-27}}</ref>

Cefpodoxime inhibits cell wall synthesis by inhibiting the final transpeptidation step of peptidoglycan synthesis in cell walls. It has well established pharmacokinetic profile with absorption of 50%. It is indicated in community acquired pneumonia, uncomplicated skin and skin structure infections, and uncomplicated urinary tract infections.

[[Image:Cefpodoxime proxetil.svg|thumb|left|250px|[[Structural formula]] of cefpodoxime '''proxetil''']]{{clear left}}

==Spectrum of bacterial susceptibility and resistance==
Cefpodoxime has been used to fight pathogenic bacteria responsible for causing gonorrhoea, tonsillitis, pneumonia, and bronchitis. Representative pathogenic genera include ''Streptococcus, Haemophilus'', and ''Neisseria''. The following represents MIC susceptibility data for a few medically significant microorganisms.
* ''[[Haemophilus influenzae]]'': ≤0.03 - 1 μg/ml
* ''Neisseria gonorrhoeae'': 0.004 - 0.06 μg/ml
* ''Streptococcus pyogenes'': ≤0.004 - 2 μg/ml
<ref>http://www.toku-e.com/Assets/MIC/Cefpodoxime%20Free%20acid.pdf</ref>

==Brand Name==
Brand Name: Toraxim (Delta Pharma Ltd. Bangladesh), Trucef (by Renata Limited, Bangladesh).

Marketed Also As : '''[http://www.meppo.com/pdf/drugs/1299-ORELOX-Adults-ans-Infants-and-Children-1321633887.pdf Orelox]''' By SanoFi-Aventis Pharma<ref>{{Cite web|title = Orelox - Drugs.com|url = http://www.drugs.com/international/orelox.html|website = www.drugs.com|accessdate = 2015-11-28}}</ref>
MAPDOX-CV Cefpodoxime and Clavulanic acid combination

MONOTAX O (Cefpodoxime)/ MONOTAX CV (Cefpodoxime and Clavulanic acid combination)- Zydus Healthcare Ltd.

==References== 
<references />

== External links ==
* {{PubChem|6526396}} - cefpodoxime proxetil
* [https://web.archive.org/web/20060325011459/https://www.pfizer.com/pfizer/download/uspi_vantin.pdf  Vantin Tablets and Oral Suspension Torpod (Torrent)Full U.S. Prescribing Information] (from manufacturer's website)
* [http://www.simplicef.com/images/simplicef_pre_info.pdf Simplicef] (from manufacturer's website)
* http://www.intaspharma.com/index.php?option=com_djcatalog2&view=itemstable&cid=3&Itemid=77
{{CephalosporinAntiBiotics}}

[[Category:Cephalosporin antibiotics]]
[[Category:Thiazoles]]
[[Category:Oximes]]